- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00645060
Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors
A Phase I Study of Yttrium-90 Labeled Humanized Anti-CEA M5A Antibody in Patients With CEA Producing Advanced Malignancies
RATIONALE: Radiolabeled monoclonal antibodies, such as yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A, can find tumor cells and carry tumor-killing substances to them without harming normal cells. This may be an effective treatment for advanced cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A in treating patients with advanced solid tumors.
Study Overview
Status
Detailed Description
OBJECTIVES:
- To establish the maximum tolerated dose of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A and describe the toxicities at each dose studied.
- To estimate radiation doses to whole body, normal organs, and tumor through serial nuclear imaging studies after intravenous infusion of the yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A.
OUTLINE: This is a dose-escalation study of yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A (MOAB M5A).
- Biodistribution: Patients receive indium In 111 radiolabeled anti-CEA MOAB M5A IV over 30 minutes. Patients undergo serial nuclear scans, single photon emission computed tomography (SPECT), and blood and urine sampling over 1 week to estimate absorbed radiation doses to tumor, normal organs (i.e., liver, lung, kidney, and bone marrow), and whole body.
- Treatment: No more than 2 weeks later, patients with adequate biodistribution receive yttrium Y 90 DOTA anti-CEA MOAB M5A IV over 30 minutes on day 1. Patients then undergo serial nuclear scans, SPECT, and blood and urine sampling over 1 week to estimate absorbed radiation doses to tumor, normal organs (i.e., liver, lung, kidney, and bone marrow), and whole body. Treatment repeats every 6-10 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
Blood and urine samples are collected periodically for analysis of total activity by radiometric high performance liquid chromatography and to acquire data on antibody metabolism and pharmacokinetics.
After completion of study treatment, patients are followed every 3 months for up to 6 months.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010-3000
- City of Hope Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed advanced solid tumor for which no standard or effective treatment is available
- Patients who refuse an available standard but non-curative treatment may also be eligible
Tumors must produce CEA as documented by either an elevated serum CEA above the upper limit of normal (ULN) or by immunohistochemical (IHC) methods
- Positive CEA IHC stain is determined if more than 30% of the tumor cells have an intensity of 2+ or greater
- Measurable disease
- Estimated < 1/3 of liver involvement if tumor involves the liver
- No brain or leptomeningeal involvement with cancer
PATIENT CHARACTERISTICS:
- Karnofsky performance status 60-100%
- Life expectancy ≥ 3 months
- WBC ≥ 4,000/μL
- ANC ≥ 1,500/μL
- Platelet count ≥ 125,000/μL
- Creatinine ≤ 1.5 mg/dL and/or creatinine clearance > 60 mL/min
- Bilirubin ≤ 1.5 mg/dL
- ALT and AST ≤ 2 times ULN
- Negative pregnancy test
- Fertile patients must use effective contraception
- Patients currently being treated for severe infections or recovering from other intercurrent illnesses (such as poorly controlled diabetes or hypertension) are ineligible until recovery is deemed complete by the investigator
- Serum anti-antibody testing must be negative for human anti-humanized antibodies (if patient received prior monoclonal antibody)
- Serum HIV-negative
- Serum hepatitis B antigen- and hepatitis C antibody-negative
PRIOR CONCURRENT THERAPY:
- At least 4 weeks since prior radiotherapy, immunotherapy, or chemotherapy (6 weeks for mitomycin C or nitrosoureas) and recovered
- Recovered from prior major surgery
- No prior radiotherapy to > 50% of bone marrow
- No other concurrent chemotherapy, radiotherapy, or immunotherapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Y-90-DOTA-M5A anti-CEA antibody
|
Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
2 days and 3-5 days post antibody infusion
Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum tolerated dose
Time Frame: 10 weeks after the beginning of the last cycle of treatment
|
10 weeks after the beginning of the last cycle of treatment
|
Toxicity
Time Frame: From the date of the beginning of the first cycle of treatment to 10 weeks from the date of the beginning of the last cycle of treatment
|
From the date of the beginning of the first cycle of treatment to 10 weeks from the date of the beginning of the last cycle of treatment
|
Overall survival
Time Frame: From 3 months after treatment completion or until death
|
From 3 months after treatment completion or until death
|
Progression-free survival
Time Frame: From 3 months after treatment completion until cancer progression or start of another treatment
|
From 3 months after treatment completion until cancer progression or start of another treatment
|
Time to progression
Time Frame: 3 months and six months after treatment completion until cancer progression or start of another treatment
|
3 months and six months after treatment completion until cancer progression or start of another treatment
|
Pharmacokinetic and molecular studies
Time Frame: At 0, 1, 4-6, 12-24, 48, 72-120 and 144-168 hours after administration of the baseline imaging dose
|
At 0, 1, 4-6, 12-24, 48, 72-120 and 144-168 hours after administration of the baseline imaging dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jeffrey Y. Wong, MD, City of Hope Comprehensive Cancer Center
- Principal Investigator: Stephen I. Shibata, MD, City of Hope Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05198
- P30CA033572 (U.S. NIH Grant/Contract)
- CHNMC-05198
- CDR0000590300 (Registry Identifier: NCI PDQ)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Adult Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
University of Texas Southwestern Medical CenterRecruitingUnspecified Adult Solid Tumor, Protocol SpecificUnited States
Clinical Trials on high performance liquid chromatography
-
University of Colorado, DenverCancer League of ColoradoActive, not recruiting
-
Brigham and Women's HospitalNational Cancer Institute (NCI)Active, not recruiting
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedProstate CancerUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Endometrial Cancer | Melanoma (Skin)Belgium
-
Iceland Genomics CorporationNational Cancer Institute (NCI)CompletedMelanoma (Skin)Iceland
-
Sociedad de Lucha Contra el Cáncer del EcuadorNot yet recruitingNeoplasms | Lymphoma, B-Cell | Cancer | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | MetabolomicsEcuador
-
OHSU Knight Cancer InstituteNational Heart, Lung, and Blood Institute (NHLBI)CompletedChronic Myeloproliferative Disorders | Fanconi Anemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
University of SheffieldUnknownBreast CancerUnited Kingdom
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedBreast Cancer | Cancer SurvivorUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed